XTL Biopharmaceuticals
XTLB
3 hedge funds and large institutions have $155K invested in XTL Biopharmaceuticals in 2017 Q2 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
60% more capital invested
Capital invested by funds: $97K → $155K (+$58K)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$29.1K |
| 2 |
Morgan Stanley
New York
|
+$2.91K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Invesco
Atlanta,
Georgia
| $82K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $52K | +$29.1K | +2,747 | +207% |
|
|
3
Morgan Stanley
New York
| $21K | +$2.91K | +275 | +20% |
|
XTLB Hedge Fund Activity: Q2 2017 in Review
3 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2017, worth a combined $155K — up 60% from $97K a quarter earlier.
Fund positioning in XTLB was balanced in Q2 2017: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $29.1K.
- 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $155K of XTL Biopharmaceuticals stock for Q2 2017, up 60% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q2 2017 and 0 closed out.
- The largest XTL Biopharmaceuticals buyer in Q2 2017 was UBS Group, an estimated $29.1K added.
Based on aggregated 13F filings for Q2 2017.